Journal for ImmunoTherapy of Cancer: 12 (11)

Commentary

Neoadjuvant immunotherapy in the evolving landscape of sarcoma treatment (24 November, 2024)
Qiyan Cai, Yi Que, Xing Zhang

Basic tumor immunology

Original research: N-terminal acetylation of transcription factor LIP induces immune therapy resistance via suppression of PD-L1 expression in non-small cell lung cancer (29 November, 2024)
Xiang He, Yongshuo Liu, Xing Gao, Feiyu Tang, Yuxi Tian, Siyuan Gong, Jia Shen, Aimin Wang, Lunquan Sun, Wensheng Wei, Liang Weng
Original research: B cell c-Maf signaling promotes tumor progression in animal models of pancreatic cancer and melanoma (27 November, 2024)
Qian Zhong, Hongying Hao, Shu Li, Yongling Ning, Hong Li, Xiaoling Hu, Kelly M McMasters, Jun Yan, Chuanlin Ding
Original research: Genetic and therapeutic heterogeneity shape the baseline and longitudinal immune ecosystem of ovarian clear cell carcinoma (27 November, 2024)
Siyu Xia, Lihua Chen, Min Yu, Jiana Li, Jiaxin Chen, Fei Xu, Mengdong Ni, Chaohua Liu, Xiaohua Wu, Xiaojun Chen, Jiajia Li
Original research: Human blood cell transcriptomics unveils dynamic systemic immune modulation along colorectal cancer progression (21 November, 2024)
Amaia Martinez-Usatorre, Laura Ciarloni, Paolo Angelino, Victoria Wosika, Alessandra Jordano Conforte, Sara S Fonseca Costa, Eric Durandau, Sylvain Monnier-Benoit, Hector Fabio Satizabal, Jérémie Despraz, Andres Perez-Uribe, Mauro Delorenzi, Stephan Morgenthaler, Brian Hashemi, Noushin Hadadi, Sahar Hosseinian-Ehrensberger, Pedro J Romero
Original research: TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion (19 November, 2024)
Anais Debesset, Caroline Pilon, Sylvain Meunier, Orianne Cuelenaere-Bonizec, Wilfrid Richer, Allan Thiolat, Claire Houppe, Matteo Ponzo, Jeanne Magnan, Jonathan Caron, Pamela Caudana, Jimena Tosello Boari, Sylvain Baulande, Nhu Han To, Benoit Laurent Salomon, Eliane Piaggio, Ilaria Cascone, José Laurent Cohen
Original research: Morphine treatment restricts response to immunotherapy in oral squamous cell carcinoma (17 November, 2024)
Lisa A McIlvried, Andre A Martel Matos, Mona M Yuan, Megan A Atherton, Fendi Obuekwe, Marci L Nilsen, Amin Reza Nikpoor, Sebastien Talbot, Tullia C Bruno, David N Taggart, Lorin K Johnson, Robert L Ferris, Dan P Zandberg, Nicole N Scheff
Original research: Inhibition of Cbl-b restores effector functions of human intratumoral NK cells (17 November, 2024)
Sofia Tundo, Marcel Trefny, Andrijana Rodić, Olivia Grueninger, Nicole Brodmann, Anastasiya Börsch, Clara Serger, Jonas Fürst, Melanie Buchi, Katarzyna Buczak, Alex T Müller, Lisa Sach-Peltason, Leyla Don, Petra Herzig, Didier Lardinois, Viola Heinzelmann-Schwarz, Kirsten D Mertz, Aljaž Hojski, Karin Schaeuble, Heinz Laubli, Marina Natoli, Alberto Toso, Thuy T Luu, Alfred Zippelius, Andrea Romagnani
Original research: YAP enhances mitochondrial OXPHOS in tumor-infiltrating Treg through upregulating Lars2 on stiff matrix (17 November, 2024)
Jingchao Bai, Meinan Yan, Yihan Xu, Youhui Wang, Yuan Yao, Peng Jin, Yuhan Zhang, Yang Qu, Liling Niu, Hui Li
Original research: FOXA1 enhances antitumor immunity via repressing interferon-induced PD-L1 expression in nasopharyngeal carcinoma (14 November, 2024)
Junshang Ge, Ying Liu, Pan Chen, Zhaoyang Zeng, Guiyuan Li, Wei Xiong, Mei Yi, Bo Xiang
Original research: Bendamustine–rituximab elicits dual tumoricidal and immunomodulatory responses via cGAS–STING activation in diffuse large B-cell lymphoma (9 November, 2024)
Ruipei Xiao, Wenli Zhao, Wei Lin, Yudian Xiao, Jie Ren, Yang Zhou, Wei Meng, Enguang Bi, Ling Jiang
Original research:
Depletion of conventional CD4⁺ T cells is required for robust priming and dissemination of tumor antigen-specific CD8⁺ T cells in the setting of anti-CD4 therapy
(9 November, 2024)
Delaney E Ramirez, Christo P C Dragnev, Tyler G Searles, Nathaniel Spicer, Tiffany Chen, J Louise Lines, Aaron R Hawkes, Wilson L Davis, Asmaa Mohamed, Keisuke Shirai, Joseph D Phillips, Pamela C Rosato, Yina H Huang, Mary Jo Turk
Original research: Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression (9 November, 2024)
Malte Roerden, Andrea B Castro, Yufei Cui, Noora Harake, Byungji Kim, Jonathan Dye, Laura Maiorino, Forest M White, Darrell J Irvine, Kevin Litchfield, Stefani Spranger

Case report

Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report (27 November, 2024)
Wenqiang Yan, Yu Xiong, Rui Lv, Chenxing Du, Tengteng Yu, Shuaishuai Zhang, Weiwei Sui, Shuhui Deng, Jigang Xiao, Yan Xu, Dehui Zou, Lugui Qiu, Gang An
Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma (17 November, 2024)
Matthew R Kudelka, Allison L Richards, Philip Friedlander, Jedd D Wolchok, Andrea P Moy, Alexander N Shoushtari

Clinical/translational cancer immunotherapy

Original research: Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study (27 November, 2024)
Caicun Zhou, Gongyan Chen, Yunchao Huang, Jianying Zhou, LiZhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi, Yi Hu, QiMing Wang, Ying Cheng, Fengying Wu, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jianan Huang, Jiuwei Cui, Lejie Cao, Yunpeng Liu, Yiping Zhang, Yueyin Pan, Jun Zhao, LiPing Wang, Jianhua Chang, Qun Chen, Xiubao Ren, Wei Zhang, Yun Fan, Zhiyong He, Jian Fang, Kangsheng Gu, XiaoRong Dong, Faguang Jin, Hongjun Gao, Guangyu An, Cuimin Ding, Xiaodong Jiang, Jianping Xiong, Xiangdong Zhou, Sheng Hu, Ping Lu, Anwen Liu, Shuliang Guo, Jianjin Huang, Chengchu Zhu, Jian Zhao, Beili Gao, Yinglan Chen, Chengping Hu, Jian Zhang, Hongmei Zhang, Hui Zhao, Zhigao Wang, Xinjing Ma, Wei Shi
Original research: Sintilimab plus HPV vaccine for recurrent or metastatic cervical cancer (27 November, 2024)
Buhai Wang, Yichen Liang, Yuechao Wu, Qiuxian Li, Yichun Zeng, Liqin Liu, Wenmiao Cao, Xiaoru Geng, Yuxiang Huang, Yinxia Wu, Jiulin Pan, Xian Zhang, J Juan Gu
Original research: Degradation of PARP1 by MARCHF3 in tumor cells triggers cCAS-STING activation in dendritic cells to regulate antitumor immunity in hepatocellular carcinoma (27 November, 2024)
Jun Cao, Bingbing Su, Chi Zhang, Rui Peng, Daoyuan Tu, Qiangwei Deng, Guoqing Jiang, Shengjie Jin, Qian Wang, Dou-Sheng Bai
Original research: Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial (21 November, 2024)
Jing Wang, Siqi Li, Hao Jiang, Ying-Jun Chang, Xiaosu Zhao, Jinsong Jia, Xiaolu Zhu, Lizhong Gong, Xiaohong Liu, Wenjing Yu, Xiaojun Huang
Original research: Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy (20 November, 2024)
Tracee L McMiller, Sepideh Besharati, Mark Yarchoan, Qingfeng Zhu, Keziban Ünsal-Kaçmaz, Ke Xu, Junghwa Lee, Feriyl Bhaijee, Logan L Engle, Janis M Taube, Alan E Berger, Robert A Anders, Suzanne L Topalian
Original research: Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors (20 November, 2024)
Matthew H Taylor, Aung Naing, John Powderly, Paul Woodard, Luke Chung, Wen Hong Lin, Hongyu Tian, Nathan Siemers, Hong Xiang, Rong Deng, Kyu Hong, Donna Valencia, Tao Huang, Ying Zhu, X Charlene Liao, Xiao Min Schebye, Manish R Patel
Original research: Natural killer cells are required for the recruitment of CD8+ T cells and the efficacy of immune checkpoint blockade in melanoma brain metastases (17 November, 2024)
Christopher Fife, Jennifer Williams, Fiona James, Scott Gregory, Tereza Andreou, Ashley Sunderland, Clive McKimmie, Rebecca J Brownlie, Robert J Salmond, Samuel Heaton, Fiona Errington-Mais, Zarnaz Hadi, David R Westhead, Marlous Hall, Alexander Davie, Amber Emmett, Mihaela Lorger
Original research: Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer (14 November, 2024)
Shipra Gandhi, Ronald T Slomba, Cayla Janes, Victoria Fitzpatrick, Janine Miller, Kristopher Attwood, Giorgio Ioannou, Sinem Ozbey, Igor De Souza, Vladimir Roudko, Prasanna Kumar, Suresh Kalathil, Kathleen M Kokolus, Jianming Wang, Eduardo Cortes Gomez, Kazuaki Takabe, Stephen Edge, Jessica Young, Helen Cappuccino, Mateusz Opyrchal, Tracey O’Connor, Ellis G Levine, Sacha Gnjatic, Pawel Kalinski
Original research: Differences in the pathological, transcriptomic, and prognostic implications of lymphoid structures between primary and metastatic cutaneous melanomas (12 November, 2024)
Lilit Karapetyan, Aofei Li, Danielle Vargas De Stefano, Hassan M Abushukair, Ayah N Al-Bzour, Andrew Knight, Caroline Layding, Hong Wang, Jin Xu, Jiqiang Yao, Xiaofei Song, Marion Joy, Jonathan Nguyen, Carlos Moran-Segura, Sabrina Bruno, Cindy Sander, Jane Messina, James J Mule, Walter J Storkus, John M Kirkwood
Original research: Correlation of safety and efficacy of atezolizumab therapy across indications (12 November, 2024)
Gonzalo Durán-Pacheco, G Scott Chandler, Vidya Maiya, Mark A Socinski, Guru Sonpavde, Javier Puente, Laurent Essioux, Corey Carter, Jose Vicente Cardona, Rajat Mohindra, Jarushka Naidoo
Original research: Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1) (20 November, 2024)
Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, Seth D Rosen, Christoper J Hoimes, Aman Chauhan, Anna Spreafico, Karl D Lewis, Debora S Bruno, Olivier Dumas, David F McDermott, James F Strauss, Quincy S Chu, Lucy Gilbert, Arvind Chaudhry, Emiliano Calvo, Rita Dalal, Valentina Boni, Marc S Ernstoff, Vamsidhar Velcheti
Original research: TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction (7 November, 2024)
David W Vredevoogd, Georgi Apriamashvili, Pierre L Levy, Sanju Sinha, Zowi R Huinen, Nils L Visser, Beaunelle de Bruijn, Julia Boshuizen, Susan E van Hal-van Veen, Maarten A Ligtenberg, Onno B Bleijerveld, Chun-Pu Lin, Judit Díaz-Gómez, Santiago Duro Sánchez, Ettai Markovits, Juan Simon Nieto, Alex van Vliet, Oscar Krijgsman, Gal Markel, Michal J Besser, Maarten Altelaar, Eytan Ruppin, Daniel S Peeper
Original research: Cancer-associated fibroblasts shape early myeloid cell response to chemotherapy-induced immunogenic signals in next generation tumor organoid cultures (4 November, 2024)
Julijan Kabiljo, Anna Theophil, Jakob Homola, Annalena F Renner, Nathalie Stürzenbecher, Daphni Ammon, Rebecca Zirnbauer, Simone Stang, Loan Tran, Johannes Laengle, Askin Kulu, Anna Chen, Markus Fabits, Velina S Atanasova, Oliver Pusch, Wolfgang Weninger, Henning Walczak, Dietmar Herndler Brandstetter, Gerda Egger, Helmut Dolznig, Anna Kusienicka, Matthias Farlik, Michael Bergmann
Original research: Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase (3 November, 2024)
Roberta Noseda, Francesca Bedussi, Valentina Giunchi, Michele Fusaroli, Emanuel Raschi, Alessandro Ceschi

Immune cell therapies and immune cell engineering

Original research: IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors (20 November, 2024)
Elizabeth Wickman, Shannon Lange, Jessica Wagner, Jorge Ibanez, Liqing Tian, Meifen Lu, Heather Sheppard, Jason Chiang, Selene C Koo, Peter Vogel, Deanna Langfitt, S Scott Perry, Raghuvaran Shanmugam, Matthew Bell, Timothy I Shaw, Giedre Krenciute, Jinghui Zhang, Stephen Gottschalk
Original research: MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity (20 November, 2024)
Meiou Liu, Yasushi Akahori, Naoko Imai, Linan Wang, Kohei Negishi, Takuma Kato, Hiroshi Fujiwara, Hiroshi Miwa, Hiroshi Shiku, Yoshihiro Miyahara
Original research: Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity (19 November, 2024)
Fien Meeus, Cyprine Neba Funeh, Robin Maximilian Awad, Katty Zeven, Dorien Autaers, Ann De Becker, Ivan Van Riet, Cleo Goyvaerts, Sandra Tuyaerts, Bart Neyns, Nick Devoogdt, Yannick De Vlaeminck, Karine Breckpot
Original research: Adoptive transfer of membrane-restricted IL-12-TCR T cells promotes antigen spreading and elimination of antigen-negative tumor variants (18 November, 2024)
Ling Zhang, Scott M Norberg, Farrah Karimipour, John S Davies, Alex Kuznetsov, Wiem Lassoued, Daniel Burnett, Philip Homan, Margaret Cam, Andrew Sinkoe, Ping Xue, James L Gulley, Christian S Hinrichs
Original research: Afatinib boosts CAR-T cell antitumor therapeutic efficacy via metabolism and fate reprogramming (17 November, 2024)
Yueyu Dai, Yue Liu, Lingna An, Fangyuan Zhong, Xi Zhang, Shifeng Lou
Original research: Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis (17 November, 2024)
Xiaojie Liang, Yufan Wang, Baiwei Luo, Bingyu Lin, WeiXiang Lu, Shengyu Tian, Dan Liu, Liang Wang
Original research:
DLL4-targeted CAR-T therapy sensitizes neoadjuvant chemotherapy via eliminating cancer stem cells and reshaping immune microenvironment in HER2⁺ breast cancer
(14 November, 2024)
Jingrui Yan, Yongjie Xie, Ziyun Liu, Yanfang Yang, Tianxing Zhou
Original research: ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis (11 November, 2024)
Lixue Cao, Haojie Peng, Yanzhen Chen, Baijin Xia, Tao Zeng, Jialing Guo, Fei Yu, Haiyan Ye, Hui Zhang, Xinxin Chen
Original research: In situ endoscopic photodynamic therapy combined with immature DC vaccination induces a robust T cell response against peritoneal carcinomatosis (5 November, 2024)
Charline Degavre, Anouk Lepez, Sebastien Ibanez, Clémence François, Katarzyna Głowacka, Céline Guilbaud, Florine Laloux-Morris, Hrag Esfahani, Davide Brusa, Caroline Bouzin, Olivier Feron

Immunotherapy biomarkers

Original research: Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC (29 November, 2024)
Hui Li, Jingjing Liu, Liang Zhang, Yu Xu, Xinyue Wang, Shaowei Lan, Peng Cui, Guoqiang Wang, Shangli Cai, Ying Cheng
Original research: Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer (28 November, 2024)
Filippo G Dall’Olio, Wael Salem Zrafi, Quentin Blampey, Francois-Xavier Danlos, Matthieu Roulleaux-Dugage, Gabriel Roman, Charles Naltet, Paul-Henry Cournède, Daniel Gautheret, Mihaela Aldea, David Planchard, Fabrice Barlesi, Aurelien Marabelle, Tyler Hulett, Nathalie Chaput-Gras, Benjamin Besse
Original research: Propafenone facilitates mitochondrial-associated ferroptosis and synergizes with immunotherapy in melanoma (24 November, 2024)
Qian Zhou, Yating Dian, Yi He, Lei Yao, Hui Su, Yu Meng, Yuming Sun, Daishi Li, Yixiao Xiong, Furong Zeng, Xiaowei Liang, Hong Liu, Xiang Chen, Guangtong Deng
Original research: Integrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy (24 November, 2024)
Tianhao Li, Shengnan Guo, Chang Xu, Mingjie Zhang, Cheng Lyu, Huanhuan Xu, Zepeng Hou, Mingshuo Zhang, Xiaobo Li, Jing Ren, Changqing Liu, Dan Kong, Dapeng Hao, Guangyu Wang
Original research: Magnitude of antigen-specific T-cell immunity the month after completing vaccination series predicts the development of long-term persistence of antitumor immune response (9 November, 2024)
John B Liao, James Y Dai, Jessica L Reichow, Jong-Baeck Lim, Katie M Hitchcock-Bernhardt, Sasha E Stanton, Lupe G Salazar, Theodore A Gooley, Mary L Disis
Original research: Body mass index and type 2 diabetes mellitus as metabolic determinants of immune checkpoint inhibitors response in melanoma (7 November, 2024)
Yu Jen Alexander Jan, Cho-Han Chiang, Soravis Osataphan, Aleigha R Lawless, Kerry L Reynolds, Ryan J Sullivan
Original research: Intratumoral and peritumoral radiomics of MRIs predicts pathologic complete response to neoadjuvant chemoimmunotherapy in patients with head and neck squamous cell carcinoma (5 November, 2024)
Peiliang Lin, Wenqian Xie, Yong Li, Chenjia Zhang, Huiqian Wu, Huan Wan, Ming Gao, Faya Liang, Ping Han, Renhui Chen, Gui Cheng, Xuekui Liu, Song Fan, Xiaoming Huang
Original research:
Role of CD47 gene expression in colorectal cancer: a comprehensive molecular profiling study
(5 November, 2024)
Hiroyuki Arai, Nishant Gandhi, Francesca Battaglin, Jingyuan Wang, Sandra Algaze, Priya Jayachandran, Shivani Soni, Wu Zhang, Yan Yang, Joshua Millstein, Jae Ho Lo, Davendra Sohal, Richard Goldberg, Michael J Hall, Aaron James Scott, Jimmy J Hwang, Emil Lou, Benjamin A Weinberg, John Marshall, Sanjay Goel, Joanne Xiu, W Michael Korn, Heinz-Josef Lenz
Original research: WWOX tuning of oleic acid signaling orchestrates immunosuppressive macrophage polarization and sensitizes hepatocellular carcinoma to immunotherapy (5 November, 2024)
Shaoqing Liu, Shiguang Yang, Min Xu, Qiang Zhou, Jialei Weng, Zhiqiu Hu, Minghao Xu, Wenxin Xu, Yong Yi, Yi Shi, Qiongzhu Dong, Mien-Chie Hung, Ning Ren, Chenhao Zhou
Original research: Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study) (3 November, 2024)
Hirokazu Shoji, Chie Kudo-Saito, Kengo Nagashima, Hiroshi Imazeki, Kai Tsugaru, Naoki Takahashi, Takeshi Kawakami, Yusuke Amanuma, Takeru Wakatsuki, Naohiro Okano, Yukiya Narita, Yoshiyuki Yamamoto, Rika Kizawa, Kei Muro, Kazunori Aoki, Narikazu Boku
Original research: Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study (3 November, 2024)
Kevin C Flanagan, Jon Earls, Jeffrey Hiken, Rachel L Wellinghoff, Michelle M Ponder, Howard L McLeod, William H Westra, Vera Vavinskaya, Leisa Sutton, Ida Deichaite, Orlan K Macdonald, Karim Welaya, James Wade, Georges Azzi, Andrew W Pippas, Jennifer Slim, Bruce Bank, Xingwei Sui, Steven E Kossman, Todd D Shenkenberg, Warren L Alexander, Katharine A Price, Jessica Ley, David N Messina, Jarret I Glasscock, A Dimitrios Colevas, Ezra E W Cohen, Douglas Adkins, Eric J Duncavage

Oncolytic and local immunotherapy

Original research: Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response (29 November, 2024)
Haoran Zhu, Wanrong Zhang, Qingguo Guo, Ruoyue Fan, Guangzuo Luo, Ying Liu
Successful treatment of in-transit metastatic melanoma with combination intralesional T-VEC and topical imiquimod immunotherapy (19 November, 2024)
Marisa Lenga, Esther Choi, Jeffrey Sosman, Sunandana Chandra, Danielle Lam, Kirsten Johnson, Lauren Schiemann, Jennifer Choi
Original research: Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors (17 November, 2024)
Diwakar Davar, Benedito A Carneiro, Grace K Dy, Siddharth Sheth, Mitesh J Borad, Kevin J Harrington, Sandip P Patel, Evanthia Galanis, Adel Samson, Sonia Agrawal, Zhongying Chen, Chunling Fan, Maozhen Gong, Jenny Burton, Eric Tu, Nicholas Durham, Kevin Laubscher, Fernanda Arnaldez, Dmitriy Zamarin

Position article and guidelines

Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events (14 November, 2024)
Malek Shatila, Hao Chi Zhang, Anusha Shirwaikar Thomas, Antonio Pizuorno Machado, Sidra Naz, Nitish Mittal, Christine Catinis, Krishnavathana Varatharajalu, Carolina Colli Cruz, Eric Lu, Deanna Wu, Julie R Brahmer, Franck Carbonnel, Stephen B Hanauer, Bret Lashner, Bryan Schneider, John A Thompson, Michel Obeid, David P Farris, Yinghong Wang

Letter

Correspondence on 'Non-invasive multimodal CT deep learning biomarker to predict pathological complete response of non-small cell lung cancer following neoadjuvant immunochemotherapy: a multicenter study' by Ye et al
(18 November, 2024)
Qiuping Ren

Main menu

Table of contents

November 2024 - Volume 12 - 11

Commentary

Basic tumor immunology

Case report

Clinical/translational cancer immunotherapy

Immune cell therapies and immune cell engineering

Immunotherapy biomarkers

Oncolytic and local immunotherapy

Position article and guidelines

Letter

Correction

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

November 2024 - Volume 12 - 11

Commentary

Basic tumor immunology

Case report

Clinical/translational cancer immunotherapy

Immune cell therapies and immune cell engineering

Immunotherapy biomarkers

Oncolytic and local immunotherapy

Position article and guidelines

Letter

Correction